Amylyx’s Relvyvrio data was, as promised, disappointing
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
So the GLP-1s strike again: Eli Lilly’s Zepbound seems to work in obstructive sleep apnea as well. Beyond that, we see up close how Amylyx’s ALS drug — which it is pulling from the market — really didn’t differ much from placebo, and see more market and investment potential for psychedelics.
Read Original Article: Amylyx’s Relvyvrio data was, as promised, disappointing »
